The Brighterside of News on MSN2h
Weight-loss drug Semaglutide could significantly reduce the risk of heart attacks
A new study, led by Professor John Deanfield from University College London (UCL), reveals that the anti-obesity medication ...
Medindia4h
How Bariatric Surgery Offers Hope for Diabetic Kidney Patients
Renoprotective Effects of Metabolic Surgery Versus GLP1 Receptor Agonists on Progression of Kidney Impairment in Patients ...
Does ‘nature’s Ozempic’ really work? Trendy GLP-1 supplements are designed to supercharge weight loss for a fraction of the price
Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...
Barchart on MSN6h
Snag This Biotech Stock Before November, Here's Why
As retail investors flock to Viking Therapeutics, the biotech firm is also catching the eye of billionaire fund managers like ...
BioWorld7h
FO-4-15, an anti-AD candidate with reduced neurotoxicity and enhanced neuroprotective effects
Researchers from the Chinese Academy of Medical Sciences reported the discovery of the 1,2,4-oxadiazole derivative FO-4-15 for the treatment of Alzheimer’s disease (AD).
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...